These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10861485)

  • 1. Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC.
    Vajkoczy P; Menger MD; Goldbrunner R; Ge S; Fong TA; Vollmar B; Schilling L; Ullrich A; Hirth KP; Tonn JC; Schmiedek P; Rempel SA
    Int J Cancer; 2000 Jul; 87(2):261-8. PubMed ID: 10861485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
    Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
    J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
    Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
    Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas.
    Seno T; Harada H; Kohno S; Teraoka M; Inoue A; Ohnishi T
    Int J Oncol; 2009 Mar; 34(3):707-15. PubMed ID: 19212676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
    Ma J; Li S; Reed K; Guo P; Gallo JM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):833-9. PubMed ID: 12626639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells.
    Read TA; Farhadi M; Bjerkvig R; Olsen BR; Rokstad AM; Huszthy PC; Vajkoczy P
    Cancer Res; 2001 Sep; 61(18):6830-7. PubMed ID: 11559558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin.
    Menon PM; Gutierrez JA; Rempel SA
    Int J Oncol; 2000 Oct; 17(4):683-93. PubMed ID: 10995878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
    Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy inhibits the recruitment of vascular accessory cells to the perivascular niche in glioma angiogenesis.
    Parmaksız G; Czabanka M; Vinci M; Vajkoczy P
    J Vasc Res; 2014; 51(2):102-9. PubMed ID: 24556643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.
    Vajkoczy P; Menger MD; Vollmar B; Schilling L; Schmiedek P; Hirth KP; Ullrich A; Fong TA
    Neoplasia; 1999 Apr; 1(1):31-41. PubMed ID: 10935468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioma cell migration is associated with glioma-induced angiogenesis in vivo.
    Vajkoczy P; Goldbrunner R; Farhadi M; Vince G; Schilling L; Tonn JC; Schmiedek P; Menger MD
    Int J Dev Neurosci; 1999; 17(5-6):557-63. PubMed ID: 10571417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
    Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
    Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
    Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo.
    Schultz C; Lemke N; Ge S; Golembieski WA; Rempel SA
    Cancer Res; 2002 Nov; 62(21):6270-7. PubMed ID: 12414657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
    Goldbrunner RH; Bendszus M; Wood J; Kiderlen M; Sasaki M; Tonn JC
    Neurosurgery; 2004 Aug; 55(2):426-32; discussion 432. PubMed ID: 15271251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Bonanno E; Scimeca M; Lacal PM; Graziani G
    J Pharmacol Exp Ther; 2018 Jan; 364(1):77-86. PubMed ID: 29025978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.